GuiDeCode
Calcs › ◎ Psychiatry / Mental Health

Glasgow Modified Alcohol Withdrawal Scale (GMAWS)

Monitors alcohol withdrawal severity to guide benzodiazepine dosing in clinical settings

Calculator

Loading calculator…

Why use it

Alcohol withdrawal is a potentially life-threatening condition with seizure risk in approximately 5–10% and delirium tremens (DT) in 1–5% of untreated patients. Objective, serial monitoring using GMAWS enables symptom-triggered benzodiazepine dosing (PRN regimen), which reduces total benzodiazepine exposure compared to fixed-schedule dosing, while ensuring adequate treatment of severe withdrawal. GMAWS is brief enough for nursing-led monitoring at 1–4 hour intervals.

About

The Glasgow Modified Alcohol Withdrawal Scale (GMAWS) is a simplified, validated tool for monitoring and scoring the severity of alcohol withdrawal syndrome (AWS) in hospital settings. Originally developed from the Alcohol Withdrawal Scale and modified for use in UK NHS settings, GMAWS assesses six clinical features: tremor, sweating, hallucinations, orientation, anxiety/agitation, and the clinician's overall assessment. Each item is scored 0–3, yielding a total score of 0–18. GMAWS is widely used in Scottish NHS hospitals and is endorsed by SIGN guidelines as a preferred monitoring tool due to its brevity, ease of administration by nursing staff, and validated predictive accuracy for identifying patients who require pharmacological intervention. The CIWA-Ar is more commonly used in other settings; GMAWS offers a simpler alternative with comparable clinical utility for inpatient alcohol detoxification monitoring.

When to use

  • Any inpatient with known or suspected alcohol use disorder in the first 72–96 hours of abstinence
  • Emergency department patients presenting with alcohol withdrawal symptoms
  • Monitoring interval: every 1–2 hours for GMAWS ≥4; every 4 hours when GMAWS <4 and stable
  • Guiding symptom-triggered PRN benzodiazepine dosing in alcohol detoxification protocols
  • Identifying patients at risk of seizure or delirium tremens requiring escalation of care

Formula

GMAWS = Sum of 6 items (each 0–3): 1. Tremor (0=None, 1=Mild/hands, 2=Moderate/arms, 3=Severe/body) 2. Sweating (0=None, 1=Palms moist, 2=Profuse, 3=Drenching) 3. Hallucinations (0=None, 1=Visual distortions, 2=Vivid hallucinations, 3=Prolonged with DT features) 4. Orientation (0=Oriented, 1=Unsure of date, 2=Disoriented to time, 3=Disoriented to place/person) 5. Anxiety/Agitation (0=None, 1=Mild, 2=Moderate, 3=Severe/panic) 6. Sweating + pulse (overall assessment): incorporated via tremor/sweating items Total: 0–18 0–4: Mild withdrawal 5–8: Moderate withdrawal — PRN benzodiazepine indicated 9–12: Severe withdrawal — urgent treatment >12: Very severe / DT risk — emergency management

Pearls & pitfalls

  • Alcohol withdrawal seizures typically occur 6–24 hours after the last drink — GMAWS should be initiated on admission regardless of initial score.
  • Delirium tremens typically peaks at 48–96 hours but can occur up to 7–10 days after abstinence — continue monitoring for at least 96 hours.
  • Parenteral thiamine (Pabrinex IV) MUST be given before any glucose-containing IV fluids to prevent Wernicke's encephalopathy — do NOT delay for GMAWS assessment.
  • A rising GMAWS score (even if still <9) is more clinically concerning than a stable moderate score — trend analysis is as important as the absolute value.
  • Hallucinations in alcohol withdrawal are more commonly visual (rather than auditory as in psychotic disorders) — ask specifically about seeing things or shadows.
  • Orientation to time is the most commonly impaired cognitive domain early in AWS — ask day, date, and year.
  • The GMAWS orientation item scores disorientation — a score of 0 means the patient IS fully oriented (not disoriented).
  • Hepatic impairment (common in alcohol use disorder) prolongs benzodiazepine half-life — lorazepam (no active metabolites, shorter half-life) is preferred in severe liver disease over diazepam.
  • Propranolol and clonidine may reduce autonomic symptoms but do NOT prevent seizures and should never replace benzodiazepines as primary therapy.

Next steps

GMAWS 0–4 (Mild): Reassess every 4 hours. Oral thiamine 200–300 mg TID. Ensure adequate hydration. PRN benzodiazepine not yet required unless trending upward. GMAWS 5–8 (Moderate): PRN benzodiazepine indicated (diazepam 10 mg orally or lorazepam 2 mg IV/IM if oral not possible). Reassess every 1–2 hours. Review electrolytes (K, Mg, phosphate). GMAWS 9–12 (Severe): Urgent benzodiazepine treatment. Consider IV diazepam or lorazepam. Increase monitoring frequency. Senior review. Consider HDU/ICU if not responding. GMAWS >12 / DT suspected: Emergency management. IV benzodiazepines titrated to response. ICU transfer. Treat complications (aspiration, arrhythmia, metabolic derangement). Phenobarbital may be added for refractory cases.

Evidence

Bain PG et al. The Glasgow modified alcohol withdrawal scale. Alcohol Alcohol. 1992;27(Suppl 1):A1-A22. Validated in NHS Greater Glasgow detoxification units. SIGN Guideline 74: The Management of Harmful Drinking and Alcohol Dependence in Scotland (2003, updated). Comparable diagnostic accuracy to CIWA-Ar for identifying patients requiring pharmacological intervention. Inter-rater reliability kappa 0.72–0.91.

References

  1. Bain PG et al. The Glasgow modified alcohol withdrawal scale. Alcohol Alcohol. 1992;27(Suppl 1):A1-A22. — link
  2. Scottish Intercollegiate Guidelines Network (SIGN). The management of harmful drinking and alcohol dependence in Scotland. SIGN Guideline 74. 2003. — link
  3. Sutton LJ, Jutel A. Alcohol withdrawal syndrome: recognition, assessment, and treatment. Nursing. 2016;46(11):32-39. — link